Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 18, Issue 4, 2004, Pages 587-606

  Meier, Juris J ^a   Nauck, Michael A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

Gastric inhibitory polypeptide; Incretin hormones; Insulin secretion; Obesity; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; FATTY ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; MESSENGER RNA; PHLORIZIN; PLACEBO; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; ENTEROGASTRONE; GASTROINTESTINAL HORMONE; PEPTIDE;

CLINICAL TRIAL; DIABETOGENESIS; DIARRHEA; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME DEGRADATION; FATTY ACID BLOOD LEVEL; FLATULENCE; FOOD INTAKE; GENE EXPRESSION; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HORMONE ACTION; HORMONE RELEASE; HUMAN; INSULIN LIKE ACTIVITY; INSULIN RELEASE; KILLER CELL; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PHARMACODYNAMICS; REVIEW; STOMACH ACID SECRETION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; GLUCAGON; GLUCOSE; HUMANS; INSULIN; LIPID METABOLISM; PEPTIDES;

EID: 8344260591     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2004.08.007     Document Type: Review

References (123)

1. J.C. Brown R.A. Pederson E. Jorpes & V. Mutt Preparation of highly active enterogastrone Canadian Journal of Physiology and Pharmacology 47 1969 113-114
2. J.C. Brown V. Mutt & R.A. Pederson Further purification of a polypeptide demonstrating enterogastrone activity Journal of Physiology 209 1970 57-64
3. J.C. Brown & J.R. Dryburgh A gastric inhibitory polypeptide. II. The complete amino acid sequence Canadian Journal of Biochemistry 49 1971 867-872
4. J.C. Brown A Gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides Canadian Journal of Biochemistry 49 1971 255-261
5. R.A. Pederson & J.C. Brown Inhibition of histamine-, pentagastrin-, and insulin-stimulated canine gastric secretion by pure gastric inhibitory polypeptide Gastroenterology 62 1972 393-400
6. J. Dupré S.A. Ross D. Watson & J.C. Brown Stimulation of insulin secretion by gastric inhibitory polypeptide in man The Journal of Clinical Endocrinology and Metabolism 37 1973 826-828
7. R.A. Pederson H.E. Schubert & J.C. Brown Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog Diabetes 24 1975 1050-1056
8. R.A. Pederson & J.C. Brown The insulinotropic action of gastric inhibitory polypeptide in the perfused rat pancreas Endocrinology 99 1976 780-785
9. R.A. Pederson & J.C. Brown Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secreton from the perfused rat pancreas Endocrinology 103 1978 610-615
10. W. Creutzfeldt The incretin concept today Diabetologia 16 1979 75-85
11. J.C. Brown & R.A. Pederson GI hormones and insulin secretion, Endocrinology Proceedings of the Fifth International Congress in Endocrinology 2 1976 568-570
12. G.I. Bell R. Sanchez-Pescador P.J. Laybourn & R.C. Najarian Exon duplication and divergence in the human preproglucagon gene Nature 304 1983 368-371
13. G.I. Bell R.F. Santerre & G.T. Mullenbach Hamster preproglucagon gene contains the sequence of glucagon and two related peptides Nature 302 1983 716-718
14. M.A. Nauck E. Bartels C. Ørskov Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations The Journal of Clinical Endocrinology and Metabolism 76 1993 912-917
15. H. Jörnvall M. Carlquist S. Kwauk et al. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP) Federal European Biochemistry Society Letters 123 1981 205-210
16. P.F. Amland R. Jorde P.G. Burhol & K-E. Giercksky Similar plasma GIP responses in obese and lean subjects after an oral test meal and after intraduodenal stimulation with fat and glucose International Journal of Obesity 8 1984 649-653
17. B. Buffa J.M. Polak A.G.E. Pearse et al. Identification of the intestinal cell storing gastric inhibitory polypeptide Histochemistry 43 1975 249-255
18. A.M.J. Buchan J.M. Polak C. Capella et al. Electron immunocytochemical evidence of the K cell localisation of gastric inhibitory polypeptide (GIP) in man Histochemistry 56 1978 37-44
19. J. Takeda Y. Seino K.I. Tanaka et al. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor Proceedings of the National Academy of Science, USA 84 1987 7005-7008
20. N. Inagaki Y. Seino Y. Takeda et al. Gastric inhibitory polypeptide: structure and chromosomal location of the human gene Molecular Endocrinology 3 1989 1014-1021
21. C.C. Tseng L.A. Jarboe S.B. Landau & M.M. Wolfe Glucose-dependent insulinotropic peptide: Structure of the precursor and tissue-specific expression in rat Proceedings of the National Academy of Science, USA 90 1993 1992-1996
22. L.I. Jepeal M.O. Boylan & M.M. Wolfe Cell-specific expression of the glucose-dependent insulinotropic polypeptide gene functions through a GATA and an ISL-1 motif in a mouse neuroendocrine tumor cell line Regulatory Peptides 113 2003 139-147
23. C.C. Tseng L.A. Jarboe & M.M. Wolfe Regulation of glucose-dependent insulinotropic peptide gene expression by a glucose meal American Journal of Physiology 266 1994 G887-G891
24. I.G. Cleator & R.H. Gourlay Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances American Journal of Surgery 130 1975 128-135
25. T. Krarup J.J. Holst & K.L. Larsen Responses and heterogeneity of IR-GIP after intraduodenal glucose and fat American Journal of Physiology 249 1985 E195-E200
26. K. Mortensen L.L. Petersen J.J. Holst et al. are colocalized in a subset of endocrine cells in the small intestine Regulatory Peptides 114 2003 189-196
27. R. Ebert & W. Creutzfeldt Decreased GIP secretion through impairment of absorption In: T.B. Wimersma Greidanus (Eds.) Frontiers in Hormone Research 1980 S. Karger Basel 192-201
28. H.S. Besterman G.C. Cook D.L. Sarson et al. Gut hormones in tropical malabsorption British Medical Journal vol. II 1979 1252-1255
29. H.S. Besterman S.R. Bloom D.L. Sarson et al. Gut-hormone profile in coeliac disease Lancet i 1978 785-788
30. R. Ebert W. Creutzfeldt J.C. Brown et al. Response of gastric inhibitory polypeptide (GIP) to test meal in chronic pancreatitis-relationship to endocrine ans exocrine insufficiency Diabetologia 12 1976 609-612
31. T. Fushiki A. Kojima T. Imoto et al. An extract of Gymnema sylvestre leaves and purified gymnemic acid inhibits glucose-stimulated gastric inhibitory peptide secretion in rats Journal of Nutrition 122 1992 2367-2373
32. R. Ebert & W. Creutzfeldt Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution Diabetologia 19 1980 198-204
33. S.E. Crockett E.L. Mazzaferri & S. Cataland Gastric inhibitory polypeptide (GIP) in maturity-onset diabetes mellitus Diabetes 25 1976 931-935
34. S.A. Ross J.C. Brown & J. Dupré Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus Diabetes 26 1977 525-529
35. I.R. Jones D.R. Owens S. Luzio et al. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus Diabetologia 32 1989 668-677
36. T. Vilsbøll T. Krarup C.F. Deacon et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients Diabetes 50 2001 609-613
37. M.B. Toft-Nielsen M.B. Damholt S. Madsbad et al. Determinants of impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients The Journal of Clinical Endocrinology and Metabolism 86 2001 3717-3723
38. R. Mentlein B. Gallwitz & W.E. Schmidt Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum European Journal of Biochemistry 214 1993 829-835
39. R.P. Pauly F. Rosche M. Wermann et al. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach Journal of Biology and Chemistry 271 1996 23222-23229
40. C.F. Deacon M.A. Nauck J.J. Meier et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide (GIP) in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide The Journal of Clinical Endocrinology and Metabolism 85 2000 3575-3581
41. L. Hansen C.F. Deacon C. Orskov & J.J. Holst Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dideptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine Endocrinology 140 1999 5356-5363
42. C. Deacon P. Danielsen L. Klarskov et al. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic effects in anesthetized pigs Diabetes 50 2001 1588-1597
43. J.J. Meier M.A. Nauck D. Kranz et al. Secretion, degradation, and elimination of glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) in patients with chronic renal insufficiency and healthy controls Diabetes 53 2004 654-662
44. T. Vilsbøll H. Agersø T. Krarup & J.J. Holst Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects The Journal of Clinical Endocrinology and Metabolism 88 2003 220-224
45. B. Moore E.S. Edie & J.H. Abram On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane Biochemistry Journal 1 1906 28-38
46. J. Dupré & J.C. Beck Stimulation of release of insulin by an extract of intestinal mucosa Diabetes 15 1966 555-559
47. M.A. Nauck M.M. Heimesaat & C. Ørskov Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus Journal of Clinical Investigation 91 1993 301-307
48. J.J. Meier K. Hücking J.J. Holst et al. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes Diabetes 50 2001 2497-2504
49. T. Vilsbøll T. Krarup S. Madsbad & J.J. Holst Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients Diabetologia 45 2002 1111-1119
50. T. Vilsbøll T. Krarup S. Madsbad & J.J. Holst Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects Regulatory Peptides 114 2003 115-121
51. J.J. Meier O. Goetze J. Anstipp et al. Gastric inhibitory polypeptide (GIP) does not inhibit gastric emptying in man American Journal of Physiology (Endocrinology and Metabolism) 286 2004 E621-E625
52. J.J. Meier M.A. Nauck N. Siepmann et al. Similar insulin secretory response to a GIP bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects Metabolism 52 2003 1579-1585
53. T. Vilsbøll F.K. Knop T. Krarup et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype The Journal of Clinical Endocrinology and Metabolism 88 2003 4897-4903
54. J.J. Meier B. Gallwitz N. Siepmann et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia Diabetologia 46 2003 798-801
55. B. Kreymann G. Williams M.A. Ghatei & S.R. Bloom Glucagon-like peptide-1 [7-36]: A physiological incretin in man Lancet 2 1987 1300-1304
56. M.A. Nauck N. Kleine C. Ørskov et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 36 1993 741-744
57. W. Creutzfeldt R. Ebert B. Willms et al. Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels Diabetologia 14 1978 15-24
58. M. Salera P. Giacomoni L. Pironi et al. Gastric inhibitory polypeptide release after oral glucose: Relationship to glucose intolerance, diabetes mellitus and obesity The Journal of Clinical Endocrinology and Metabolism 55 1982 329-336
59. S.A. Ross & J. Dupré Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on response to intravenous glucose in normal and diabetic subjects Diabetes 27 1978 327-333
60. J.M. Falko S.E. Crockett S. Cataland & E.L. Mazzaferri Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man The Journal of Clinical Endocrinology and Metabolism 41 1975 260-265
61. R.G. Yip M.M. Wolfe GIP biology and fat metabolism Life Sciences 66 2000 91-103
62. T.B. Usdin É. Mesey D.C. Button Gastric et al. inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor familiy, is widely distributed in peripheral organs and the brain Endocrinology 133 1993 2861-2870
63. R.H. Eckel W.Y. Fujimoto J.D. Brunzell Gastric inhibitory polypeptide enhance lipoprotein lipase activity in cultured preadipocytes Diabetes 28 1979 1141-1142
64. H. Hauner G. Glatting D. Kaminska E.F. Pfeiffer Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes Annals of Nutrition and Metabolism 32 1988 282-288
65. T. Wasada K. McCorkle V. Harris et al. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs Journal of Clinical Investigation 68 1981 1107-1110
66. R. Ebert M. Nauck W. Creutzfeldt Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride response in rats Hormone and Metabolic Research 23 1991 517-521
67. A. Ohneda T. Kobayashi J. Hihei Effect of enogenous gastric inhibitory polypeptide (GIP) on the removal of triacylglycerol in dogs Regulatory Peptides 6 1983 25-32
68. K. Miyawaki Y. Yamada N. Ban et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity Nature Medicine 8 2002 738-742
69. V.A. Gault F.P. O'Harte P.R. Flatt Glucose-dependent insulinotropic polypeptide (GIP): Anti-diabetic and anti-obesity potential? Neuropeptides 37 2003 253-263
70. T.J. Kieffer GIP or not GIP? That is the question Trends of Pharmacology Science 24 2003 110-112
71. C.-C. Tseng T.J. Kieffer L.A. Jarboe et al. Postprandial stimulation of insulin release by glucose-dependent insulinotropic peptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat Journal of Clinical Investigation 98 1996 2440-2445
72. K. Miyawaki Y. Yamada H. Yano Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice Proceedings of the National Academy of Science, USA 96 1999 14843-14847
73. M.M. Wolfe M.P. Hocking D.G. Maico J.E. McGuigan Effects of antibodies to gastric inhibitory peptide on gastric acid secretion and gastrin release in the dog Gastroenterology 84 1983 941-948
74. V. Maxwell A. Shulkes J.C. Brown et al. Effect of gastric inhibitory polypeptide on pentagastrin-stimulated acid secretion in man Digestive Diseases and Sciences 24 1980 113-116
75. M.A. Nauck E. Bartels C. Ørskov et al. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects Digestion 52 1992 214-221
76. P. Thor J. Laskiewicz J.W. Konturek et al. Role of GIP and insulin in glucose-induced changes in intestinal motility patterns American Journal of Physiology 252 Pt 1 1987 G8-G12
77. C.G. Nicholl G. Carolan H. Sevelius S.R. Bloom Effect of enprostil on gastric emptying, intestinal transit time and post-prandial release of gastro-intestinal peptides Digestion 43 1989 47-55
78. A. Wettergren B. Schjoldager P.E. Mortensen et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man Digestive Diseases and Sciences 38 1993 665-673
79. M.A. Nauck U. Niedereichholz R. Ettler et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans American Journal of Physiology (Endocrinology and Metabolism) 273 1997 E981-E988
80. J.J. Meier B. Gallwitz S. Salmen et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes The Journal of Clinical Endocrinology and Metabolism 88 2003 2719-2725
81. J. Gromada J.J. Holst P. Rorsman Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1 Pflügers Archives 435 1998 583-594
82. T. Kosaka R.K.S. Lim Demonstration of the humoral agent in fat inhibition on gastric secretion Proceedings of the Society of Experimental Biology Medicine 27 1930 890-891
83. W. Creutzfeldt R. Ebert New developments in the incretin concept Diabetologia 28 1985 565-573
84. H. Elrick L. Stimmler C.J. Hlad Y. Arai Plasma insulin response to oral and intravenous glucose administration The Journal of Clinical Endocrinology and Metabolism 24 1964 1076-1082
85. L.T. Shuster V.L.W. Go R.A. Rizza et al. Incretin effect due to increased secretion and decreased clearance of insulin in normal humans Diabetes 37 1988 200-203
86. M.A. Nauck E. Homberger E.G. Siegel et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses The Journal of Clinical Endocrinology and Metabolism 63 1986 492-498
87. T. Krarup Immunoreactive gastric inhibitory polypeptide Endocrine Reviews 9 1988 122-133
88. T. Kosaka R.K.S. Lim Demonstration of the humoral agent in fat inhibition of gastric acid secretion Proceedings of the Society of Experimental Biology Medicine 27 1930 870-891
89. M.K. Gutniak J.J. Holst C. Ørskov et al. Antidiabetogenic effect of glucagon-like peptid e-1 (7-36)amide in normal subjects and patients with diabetes mellitus New England Journal of Medicine 326 1992 1316-1322
90. P.F. Amland R. Jorde S. Aanderup et al. Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state Scandinavian Journal of Gastroenterology 20 1985 315-320
91. R. Jorde P.G. Burhol The insulinotropic effect of gastric inhibitory polypeptide in non-insulin dependent diabetes Italian Journal of Gastroenterology 19 1987 76-78
92. T. Krarup N. Saurbrey A.J. Moody et al. Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus Metabolism 36 1988 677-682
93. J.J. Holst J. Gromada M.A. Nauck The pathogenesis of NIDDM involves a defective expression of the GIP receptor Diabetologia 40 1997 984-986
94. J.J. Meier M.A. Nauck W.E. Schmidt B. Gallwitz Gastric inhibitory polypeptide (GIP): The neglected incretin revisited Regulatory Peptides 107 2002 1-13
95. T.W. Van Haeften W.W. Van Maarschalkerweerd J.E. Gerich E.A. Van der Veen Decreased insulin secretory capacity and normal pancreatic B-cell glucose sensitivity in non-obese patients with NIDDM European Journal of Clinical Investigation 21 1991 168-174
96. A. Fritsche N. Stefan E. Hardt et al. Characterisation of beta-cell dysfunction of impaired glucose tolerance: Evidence for impairment of incretin-induced insulin secretion Diabetologia 43 2000 852-858
97. K. Ratheiser W. Reitgruber M. Komjati et al. Quantitative and qualitative differences in basal and glucose- and arginine-stimulated insulin secretion in healthy subjects and different stages of NIDDM Acta Diabetologica Latina 27 1990 197-213
98. L. Groop L. Luzi A. Melander et al. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects Diabetes 36 1987 1320-1328
99. B. Thorens A. Porret L. Buhler et al. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor Diabetes 42 1993 1678-1682
100. B. Gallwitz M. Witt U.R. Fölsch et al. Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells Journal of Molecular Endocrinology 10 1993 259-268
101. R. Göke M.E. Trautmann E. Haus et al. Signal transmission after GLP-1(7-36)amide binding in RINm5F cells American Journal of Physiology 257 1989 G397-G401
102. J. Gromada W.G. Ding S. Barg et al. Multisite regulation of insulin secretion by cAMP-increasing agonists: Evidence that glucagon-like peptide 1 and glucagon act via distinct receptors Pflügers Archives 434 1997 515-524
103. I.R. Jones D.R. Owens A.J. Moody et al. The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion Diabetologia 30 1987 707-712
104. F.P. O'Harte A.M. Gray P.R. Flatt Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle The Journal of Endocrinology 156 1998 237-243
105. F.P. O'Harte V.A. Gault J.C. Parker et al. Improved stability, insulin-releasing activity and anti-diabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP Diabetologia 45 2002 1281-1291
106. V.A. Gault P.R. Flatt C.J. Bailey et al. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant anti-hyperglycaemic activity in spontaneous obesity-diabetes Biochemistry Journal 367 Pt 3 2002 913-920
107. V.A. Gault F.P. O'Harte P. Harriott P.R. Flatt Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide Biochemistry Biophysics Research Communications 290 2002 1420-1426
108. S.A. Hinke R.W. Gelling R.A. Pederson et al. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats Diabetes 51 2002 652-661
109. V.A. Gault N. Irwin P. Harriott et al. DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP Cell Biology International 27 2003 41-46
110. V.A. Gault P.R. Flatt P. Harriott et al. Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide The Journal of Endocrinology 176 2003 133-141
111. V.A. Gault F.P. O'Harte P. Harriott P.R. Flatt Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo Metabolism 52 2003 679-687
112. F.P. O'Harte M.H. Mooney P.R. Flatt NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced anti-hyperglycemic activity Diabetes 48 1999 758-765
113. F.P. O'Harte Y.H. Abdel-Wahab J.M. Conlon P.R. Flatt Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells Biochemistry Biophysics Acta 1425 1998 319-327
114. F.P. O'Harte M.H. Mooney C.M. Kelly P.R. Flatt Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide The Journal of Endocrinology 165 2000 639-648
115. F.P.M. O'Harte V.A. Gault P. Harriott et al. DPP IV resistant N-terminally modified GIP analogues with enhanced insulinotropic activity Diabetologia 44 supplement 1 2001 A194
116. R. Eissele R. Göke S. Willemer et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man The European Journal of Clinical Investigation 22 1992 283-291
117. C. Ørskov L. Rabenhej A. Wettergren et al. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans Diabetes 43 1994 535-539
118. B.T. Schjoldager P.E. Mortensen J. Christiansen et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans Digestive Diseases and Sciences 34 1989 703-708
119. A. Sauerwald M.A. Nauck J.J. Holst W.H. Schmiegel Influence of glucagon-like peptide 1 on fasting hyperglycaemia in NIDDM patients treated with insulin (sulfonylurea failure) Diabetologia 40 supplement 1 1997 A46
120. R. Perfetti J. Zhou M.E. Doyle J.M. Egan Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats Endocrinology 141 2000 4600-4605
121. A. Trümper K. Trümper H. Trusheim et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling Molecular Endocrinology 15 2001 1559-1570
122. M. Nauck W.E. Schmidt R. Ebert et al. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man; interactions with glucose, phenylalanine, and cholezystokinin-8 The Journal of Clinical Endocrinology and Metabolism 69 1989 654-662
123. P. Fieseler S. Bridenbaugh R. Nustede et al. Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8 American Journal of Physiology 268 1995 E949-E955